Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

Hasselbalch, Hans Carl

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. [electronic resource] - American journal of hematology Dec 2003 - 238-42 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article

0361-8609

10.1002/ajh.10431 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Benzamides
Female
Humans
Hydroxyurea--therapeutic use
Imatinib Mesylate
Interferon-alpha--therapeutic use
Leukocytosis--chemically induced
Male
Middle Aged
Piperazines--administration & dosage
Polycythemia--complications
Primary Myelofibrosis--drug therapy
Pyrimidines--administration & dosage
Thrombocytosis--chemically induced
Treatment Outcome